Details
Stereochemistry | ACHIRAL |
Molecular Formula | C19H18N2O3 |
Molecular Weight | 322.3578 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(=O)CCC1C(=O)N(N(C1=O)C2=CC=CC=C2)C3=CC=CC=C3
InChI
InChIKey=LGYTZKPVOAIUKX-UHFFFAOYSA-N
InChI=1S/C19H18N2O3/c1-14(22)12-13-17-18(23)20(15-8-4-2-5-9-15)21(19(17)24)16-10-6-3-7-11-16/h2-11,17H,12-13H2,1H3
DescriptionSources: http://www.pharmazie.com/graphic/A/24/0-13524.pdf
Sources: http://www.pharmazie.com/graphic/A/24/0-13524.pdf
Kebuzone is a cyclooxygenase inhibitor that was used for the treatment of different inflammatory conditions such as thrombophlebitis and rheumatoid arthritis. The current marketing status of the drug is unknown and supposed to be discontinued.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2094253 Sources: http://www.pharmazie.com/graphic/A/24/0-13524.pdf |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | KETAZON Approved UseInflammatory and degenerative inflammatory activated forms of rheumatism; rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, neuritis and neuralgia as cervical syndrome, lumbago, sciatica, gout; rheumatism; painful inflammation after injury or surgery; thrombophlebitis. |
|||
Palliative | KETAZON Approved UseInflammatory and degenerative inflammatory activated forms of rheumatism; rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, neuritis and neuralgia as cervical syndrome, lumbago, sciatica, gout; rheumatism; painful inflammation after injury or surgery; thrombophlebitis. |
PubMed
Title | Date | PubMed |
---|---|---|
[Intrahepatic cholestasis following ketazone successfully treated using the enzyme inductor phenobarbital]. | 1978 Apr |
|
Screening procedure for detection of non-steroidal anti-inflammatory drugs and their metabolites in urine as part of a systematic toxicological analysis procedure for acidic drugs and poisons by gas chromatography-mass spectrometry after extractive methylation. | 2001 May-Jun |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: http://www.pharmazie.com/graphic/A/24/0-13524.pdf
1 (250 mg) to 2 dragees 3 times daily
Route of Administration:
Oral
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
M01AA06
Created by
admin on Fri Dec 15 16:36:56 GMT 2023 , Edited by admin on Fri Dec 15 16:36:56 GMT 2023
|
||
|
WHO-VATC |
QM01AA06
Created by
admin on Fri Dec 15 16:36:56 GMT 2023 , Edited by admin on Fri Dec 15 16:36:56 GMT 2023
|
||
|
NCI_THESAURUS |
C257
Created by
admin on Fri Dec 15 16:36:56 GMT 2023 , Edited by admin on Fri Dec 15 16:36:56 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
2444
Created by
admin on Fri Dec 15 16:36:56 GMT 2023 , Edited by admin on Fri Dec 15 16:36:56 GMT 2023
|
PRIMARY | |||
|
Kebuzone
Created by
admin on Fri Dec 15 16:36:56 GMT 2023 , Edited by admin on Fri Dec 15 16:36:56 GMT 2023
|
PRIMARY | |||
|
DB08940
Created by
admin on Fri Dec 15 16:36:56 GMT 2023 , Edited by admin on Fri Dec 15 16:36:56 GMT 2023
|
PRIMARY | |||
|
4VD83UL6Y6
Created by
admin on Fri Dec 15 16:36:56 GMT 2023 , Edited by admin on Fri Dec 15 16:36:56 GMT 2023
|
PRIMARY | |||
|
28198
Created by
admin on Fri Dec 15 16:36:56 GMT 2023 , Edited by admin on Fri Dec 15 16:36:56 GMT 2023
|
PRIMARY | RxNorm | ||
|
31749
Created by
admin on Fri Dec 15 16:36:56 GMT 2023 , Edited by admin on Fri Dec 15 16:36:56 GMT 2023
|
PRIMARY | |||
|
212-715-7
Created by
admin on Fri Dec 15 16:36:56 GMT 2023 , Edited by admin on Fri Dec 15 16:36:56 GMT 2023
|
PRIMARY | |||
|
SUB08363MIG
Created by
admin on Fri Dec 15 16:36:56 GMT 2023 , Edited by admin on Fri Dec 15 16:36:56 GMT 2023
|
PRIMARY | |||
|
CHEMBL2107720
Created by
admin on Fri Dec 15 16:36:56 GMT 2023 , Edited by admin on Fri Dec 15 16:36:56 GMT 2023
|
PRIMARY | |||
|
100000082866
Created by
admin on Fri Dec 15 16:36:56 GMT 2023 , Edited by admin on Fri Dec 15 16:36:56 GMT 2023
|
PRIMARY | |||
|
C79126
Created by
admin on Fri Dec 15 16:36:56 GMT 2023 , Edited by admin on Fri Dec 15 16:36:56 GMT 2023
|
PRIMARY | |||
|
3824
Created by
admin on Fri Dec 15 16:36:56 GMT 2023 , Edited by admin on Fri Dec 15 16:36:56 GMT 2023
|
PRIMARY | |||
|
DTXSID00234500
Created by
admin on Fri Dec 15 16:36:56 GMT 2023 , Edited by admin on Fri Dec 15 16:36:56 GMT 2023
|
PRIMARY | |||
|
C100280
Created by
admin on Fri Dec 15 16:36:56 GMT 2023 , Edited by admin on Fri Dec 15 16:36:56 GMT 2023
|
PRIMARY | |||
|
m6606
Created by
admin on Fri Dec 15 16:36:56 GMT 2023 , Edited by admin on Fri Dec 15 16:36:56 GMT 2023
|
PRIMARY | Merck Index | ||
|
853-34-9
Created by
admin on Fri Dec 15 16:36:56 GMT 2023 , Edited by admin on Fri Dec 15 16:36:56 GMT 2023
|
PRIMARY | |||
|
1522
Created by
admin on Fri Dec 15 16:36:56 GMT 2023 , Edited by admin on Fri Dec 15 16:36:56 GMT 2023
|
PRIMARY |
ACTIVE MOIETY